Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on April 24, 2020, regarding an event that occurred on April 21, 2020. The filing discloses the execution of an Amended and Restated Executive Employment Agreement with Thomas F. Isett 3rd, the Company's Chief Executive Officer and Executive Co-Chairman.
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $490,000 annually.
- Signing Bonus: $450,000 paid upon execution of the original agreement; an additional $250,000 cash bonus payable on March 10, 2021, contingent on continued employment.
- Guaranteed Bonus: $80,000 for the fiscal year ending June 30, 2020.
- Incentive Bonus: Up to 60% of base salary for fiscal years beginning on or after July 1, 2020, subject to performance criteria.
- Equity Grant: Option to purchase 975,000 shares of common stock with an exercise price at fair market value on the grant date.
- Change of Control Bonus: 4.5% of transaction consideration if a qualifying Change of Control Transaction occurs.
Material Changes Versus Prior Period
The Amended Employment Agreement modifies the terms of the Executive Employment Agreement dated March 10, 2020. The primary material change is the removal of a provision in the Original Agreement that required the Company to exchange the stock option with a new option if the trading price of the Company's securities fell below the exercise price at specified intervals. All other terms remain unchanged from the Original Agreement.
Guidance, Outlook, and Risks
Management Commentary and Terms:
- Equity Vesting: The 975,000-share option vests ratably over 36 months from the date of the Original Agreement (March 10, 2020). The option is fully vested upon a Change of Control Transaction.
- Termination Provisions:
- For Cause: Entitled to accrued salary and benefits only.
- Without Cause/Disability: Entitled to base salary and accrued bonus for the lesser of 24 months or the remaining term of the agreement.
- Change of Control: Entitled to a lump sum equal to 24 months of base salary, a pro-rated target annual bonus, 12 months of health benefits, and immediate 100% vesting of unvested equity awards.
- Benefits: Full cost of medical, vision, and dental benefits for the executive and family; up to $7,500 annually for continuing education; and reimbursement for relocation expenses if required.
Risks and Contingencies: The filing notes that the employment is "at will" and may be terminated at any time by either party. The financial impact of the signing bonus and guaranteed bonus is contingent on the executive remaining employed through specific dates.
Important Facts for Investor Verification
- Verify the removal of the "price floor" protection on the CEO's stock option grant compared to the March 2020 agreement.
- Confirm the total cash compensation obligation for the fiscal year ending June 30, 2020, including the $80,000 guaranteed bonus and the $250,000 deferred signing bonus.
- Review the specific definition of "Change of Control Transaction" in the attached Exhibit 10.1 to understand the threshold for the 4.5% transaction bonus and accelerated vesting.
- Assess the dilution impact of the 975,000 share option grant under the 2018 Omnibus Equity Incentive Plan.